$OXGN $PCYC Phase II news from 6/6/2011

SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that encouraging final results from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) in patients with anaplastic thyroid cancer (ATC) were presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois, by Julie Sosa, M.D., Associate Professor of Surgery and of Medicine at Yale University, and primary investigator in the study.

http://tinyurl.com/3vbocfe

SUNNYVALE, Calif., June 6, 2011 /PRNewswire/ — Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting. The company will also provide a clinical development program update for the Btk Inhibitor, PCI-32765.  The update will include 1) efficacy from the Phase IA trial of PCI-32765 in B-cell malignancies including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 2) a status update for ongoing PCI-32765 clinical studies, and 3) an update on future clinical trials including program expansion opportunities in follicular lymphoma and multiple myeloma.  The company will also provide information on the Non-Hodgkins Lymphoma (NHL) market. An investor conference call to discuss the clinical trial results and other company updates will be hosted today at 4:30pm ET, further information is provided below.  Slide presentations will be posted on the Pharmacyclics website including the ASCO presentation of the Phase IB/II study results and the Investor Relations presentation.  

http://tinyurl.com/6el7az2